Perrigo Company plc completed the sale of its Dermacosmetics business to Karo Healthcare on April 30, 2026, for a total consideration of up to €332.6 million. The deal includes €305.6 million in upfront cash and an additional €27.0 million in contingent payments that will be earned over three years if the divested brands meet specified sales milestones.
The divested portfolio comprises the ACO, Biodermal, Emolium, and Iwostin brands, which generated approximately €120 million in net sales in 2025 and represented about 5% of Perrigo’s adjusted operating income that year. By shedding this segment, Perrigo is concentrating its resources on core self‑care categories that drive higher growth and margin potential.
The transaction is a key component of Perrigo’s “Three‑S” plan—Stabilize, Streamline, and Strengthen—designed to trim non‑core assets, reduce debt, and sharpen the company’s focus. Karo Healthcare, a KKR‑owned specialty skincare firm, is expanding its presence in Northern Europe and the Polish market through this acquisition, aligning with KKR’s expertise in corporate carve‑outs.
Patrick Lockwood‑Taylor, Perrigo’s President and CEO, said, “This transaction marks another important milestone in the execution of our Three‑S plan to Stabilize, Streamline, and Strengthen the Company. By further streamlining our portfolio and sharpening our focus on core categories, we are better positioned to leverage our competitive advantages and deliver more consistent and sustainable growth in shareholder value. Importantly, we expect the net proceeds from this transaction will be used primarily to reduce debt, enhancing our financial flexibility and strengthening our balance sheet.”
The €305.6 million of upfront cash will be applied to reduce Perrigo’s total debt, which stood at $3.85 billion as of the end of the previous fiscal year. The debt‑to‑equity ratio, previously 1.31, is expected to decline as the company’s leverage improves, providing a stronger balance sheet and greater capacity for future investment or shareholder returns.
The divestiture follows a period of mixed earnings results, including a Q4 2025 report that missed analyst expectations on earnings per share. By completing this sale, Perrigo signals a decisive shift toward a leaner, more focused business model, aiming to stabilize earnings and create a clearer path for sustainable growth.”
revised_sentiment_rating":2} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.